Evidence map

ReviewAntibodies (Basel, Switzerland)2026

Potential Mechanisms of Partial/Transient Response or Resistance to Daratumumab Therapy: A Focus on Anti-Daratumumab Antibodies and Urinary Daratumumab Loss.

Marco Allinovi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Full record →Abstract, authors, funding and every citing paper · PMID 42496283